Phase I trial of rosiglitazone in FSGS: I. Report of the font study group

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 1, 2009, Pages 39-47

  Joy, Melanie S ^a,b   Gipson, Debbie S ^a   Dike, Mary ^a   Powell, Leslie ^a   Thompson, Amber ^a   Vento, Suzanne ^c   Eddy, Allison ^d   Fogo, Agnes B ^e   Kopp, Jeffrey B ^f   Cattran, Daniel ^g   Trachtman, Howard ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; DEXAMETHASONE; DIPHENHYDRAMINE; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ROSIGLITAZONE; TACROLIMUS; 2,4 THIAZOLIDINEDIONE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; SERUM ALBUMIN; STEROID;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; KIDNEY BIOPSY; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; PENILE SWELLING; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA; WEIGHT GAIN; AGE; BODY SURFACE; CANADA; DRUG EFFECT; DRUG RESISTANCE; KIDNEY; METABOLISM; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROTEINURIA; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; BODY SURFACE AREA; CANADA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; PROTEINURIA; SERUM ALBUMIN; STEROIDS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 64049094897     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02310508     Document Type: Article

References (23)

1. Weissgarten J, Berman S, Efrati S, et al: Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats. Nephrol Dial Transplant 21: 1198-1204, 2006
2. Panchapakesan U, Sumual S, Pollock CA, et al: PPAR-γ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 289: F1153-F1158, 2005 (Pubitemid 41447072)
3. Zafiriou S, Stanners SR, Saad S, et al: Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 16: 638-645, 2005 (Pubitemid 41725100)
4. Yang HC, Ma LJ, Ma J, Fogo AB Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 69: 1756-1764, 2006 (Pubitemid 43739202)
5. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI:Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 17: 7-12, 2003 (Pubitemid 36163426)
6. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE: Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 24: 2047-2055, 2006
7. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, Rosiglitazone Clinical Trials Study Group:Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86: 280-288, 2001
8. Kincaid-Smith P, Fairley KF, Farish S, Best JD, Proietto J. Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton) 13: 58-62, 2008
9. Rosiglitazone Prescribing Information. Research Triangle Park, NC, GlaxoSmithKline, 2007
10. Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J:Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 17: 2363-2367, 2006 (Pubitemid 44300952)
11. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL: Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73: 427-434, 2003 (Pubitemid 36549827)
12. Leblond FA, Giroux L, Villeneuve JP, Pichette V: Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 28: 1317-1320, 2000 (Pubitemid 30797115)
13. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR: Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2: 12, 2004 (Pubitemid 39112018)
14. Anderson BJ, Holford NH: Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48: 303-332, 2008
15. Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI: Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 43: 252-259, 2003 (Pubitemid 36232653)
16. Muxlow AM, Fowles S, Russell P: Automated high-performance liquid chromatography method for the determination of rosiglitazone in human plasma. J Chromatogr B Biomed Sci Appl 752: 77-84, 2001 (Pubitemid 32141195)
17. Nolin T, Naud J, Leblond F, Pichette V: Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83: 898-903, 2008 (Pubitemid 351704931)
18. Michaud J, Dube P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V: Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 144: 1067-1077, 2005 (Pubitemid 40593005)
19. Michaud J, Naud J, Chouinard J, Desy F, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V: Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol 17: 3041-3048, 2006 (Pubitemid 44707764)
20. Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, Jetter A, Stehle S, Tsahuridu M, Meineke I, Brockmöller J, Fuhr U: Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 80: 657-667, 2006 (Pubitemid 44920222)
21. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471, 2007 (Pubitemid 46919772)
22. Krall RL: Cardiovascular safety of rosiglitazone. Lancet 369: 1995-1996, 2007
23. Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G: Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 17: 3482-3490, 2005 (Pubitemid 44865290)